Mount Sinai Health System and IBM Research today announced the launch of the Phenotypes Reimagined to Define Clinical Treatment and Outcome Research (PREDiCTOR) study. The research effort aims to address the lack of objective measures in psychiatry by leveraging advances in artificial intelligence and incorporating rich behavioral data from clinical interviews, at-home data captured on smartphones, and cognitive testing. The goal is to predict outcomes such as treatment discontinuation, hospitalizations, and emergency room visits for young people who are seeking mental health evaluation and treatment. The study will be conducted in collaboration with researchers from Harvard, Johns Hopkins, Columbia, and Carnegie Mellon universities and Deliberate AI.
Funded by a $20 million grant from the National Institute of Mental Health (NIMH), the PREDiCTOR study brings together a team of leading clinical investigators, artificial intelligence experts, and data scientists. The team will use objective, scalable, and cost-effective measurements to define novel clinical signatures that can be used for individual-level prediction and clinical decision-making in treating mental health disorders.
The research project will be co-led by Rene Kahn, MD, PhD, Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System; Cheryl Corcoran, MD, Program Leader in Psychosis Risk for Icahn Mount Sinai; and Guillermo Cecchi, PhD, Director of the Computational Psychiatry and Neuroimaging groups in IBM Research. Collaborators from Harvard, Johns Hopkins, Columbia, and Carnegie Mellon universities and Deliberate.ai will contribute to the work as well.